Abstract
In this consensus statement, we provide updated recommendations on multiple sclerosis (MS) management during the COVID-19 crisis and the post-pandemic period applicable to neurology services around the world. Statements/recommendations were generated based on available literature and the experience of 13 MS expert panelists using a modified Delphi approach online. The statements/recommendations give advice regarding implementation of telemedicine; use of disease-modifying therapies and management of MS relapses; management of people with MS at highest risk from COVID-19; management of radiological monitoring; use of remote pharmacovigilance; impact on MS research; implications for lowest income settings, and other key issues.
| Original language | English |
|---|---|
| Article number | 577627 |
| Number of pages | 13 |
| Journal | Journal of Neuroimmunology |
| Volume | 357 |
| DOIs | |
| Publication status | Published - 15 Aug 2021 |
Keywords
- COVID-19
- Disease-modifying treatment
- Multiple sclerosis
- Pharmacovigilance
- Telemedicine
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic : An international consensus statement. / Reyes, Saúl; Cunningham, Anthony L.; Kalincik, Tomas et al.
In: Journal of Neuroimmunology, Vol. 357, 577627, 15.08.2021.Research output: Contribution to journal › Review Article › Research › peer-review
TY - JOUR
T1 - Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic
T2 - An international consensus statement
AU - Reyes, Saúl
AU - Cunningham, Anthony L.
AU - Kalincik, Tomas
AU - Havrdová, Eva Kubala
AU - Isobe, Noriko
AU - Pakpoor, Julia
AU - Airas, Laura
AU - Bunyan, Reem F.
AU - van der Walt, Anneke
AU - Oh, Jiwon
AU - Mathews, Joela
AU - Mateen, Farrah J.
AU - Giovannoni, Gavin
N1 - Funding Information: S. Reyes has received speaking honoraria or scientific advisory fees from Merck, Novartis and Biogen; A.L. Cunningham's institution has received speaking honoraria or scientific advisory fees from Merck; T. Kalincik served on scientific advisory boards for Roche, Sanofi Genzyme, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Sanofi Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Sanofi Genzyme, Teva, BioCSL and Merck and received research or educational event support from Biogen, Novartis, Genzyme, Roche, Celgene and Merck; E. Kubala Havrdová has received honoraria/research support from Biogen, Merck Serono, Novartis, Roche, and Teva; has served as a member of advisory boards for Actelion, Biogen, Celgene, Merck Serono, Novartis, and Sanofi Genzyme; has been supported by the Czech Ministry of Education research project PROGRES Q27/LF1; N. Isobe has received speaking honoraria from Novartis Pharma, Biogen Japan, Mitsubishi Tanabe Pharma, Alexion, and Takeda Pharmaceutical Company; J. Pakpoor has received speaking honoraria/scientific advisory board fees from EMD Serono; L. Airas has received institutional research grants from Merck Serono and Sanofi Genzyme. She has obtained compensation for advisory board work from Roche, Biogen Idec, Sanofi Genzyme and Merck Serono; R.F. Bunyan has received speaker honoraria and travel support from Merck, Novartis, and Roche; A. van der Walt served on advisory boards and receives unrestricted research grants from Novartis, Biogen, Merck and Roche She has received speaker's honoraria and travel support from Novartis, Roche, and Merck. She receives grant support from the National Health and Medical Research Council of Australia and MS Research Australia; J. Oh has received grants from MS Society of Canada, Love-Barford Endowment of St. Michael's Hospital Foundation, National MS Society, Brain Canada, Biogen Idec, Roche, and EMD Serono; and personal fees for consulting or speaking from Biogen Idec, EMD Serono, Roche, Sanofi Genzyme, Novartis, and Celgene; J. Mathews has received conference sponsorship and hospitality payments from Biogen, Celegene, Merck, Novartis, Roche, and Sanofi; F.J. Mateen has received consulting fees and research support from Biogen; G. Giovannoni has received consultancy, presentation fees or grants from AbbVie Biotherapeutics, Bayer Healthcare, Biogen, Canbex, Celgene, Ironwood, Japan Tobacco, Novartis, Roche, Sanofi Genzyme, Synthon, Takeda, Teva and Vertex. Publisher Copyright: © 2021 Elsevier B.V. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/8/15
Y1 - 2021/8/15
N2 - In this consensus statement, we provide updated recommendations on multiple sclerosis (MS) management during the COVID-19 crisis and the post-pandemic period applicable to neurology services around the world. Statements/recommendations were generated based on available literature and the experience of 13 MS expert panelists using a modified Delphi approach online. The statements/recommendations give advice regarding implementation of telemedicine; use of disease-modifying therapies and management of MS relapses; management of people with MS at highest risk from COVID-19; management of radiological monitoring; use of remote pharmacovigilance; impact on MS research; implications for lowest income settings, and other key issues.
AB - In this consensus statement, we provide updated recommendations on multiple sclerosis (MS) management during the COVID-19 crisis and the post-pandemic period applicable to neurology services around the world. Statements/recommendations were generated based on available literature and the experience of 13 MS expert panelists using a modified Delphi approach online. The statements/recommendations give advice regarding implementation of telemedicine; use of disease-modifying therapies and management of MS relapses; management of people with MS at highest risk from COVID-19; management of radiological monitoring; use of remote pharmacovigilance; impact on MS research; implications for lowest income settings, and other key issues.
KW - COVID-19
KW - Disease-modifying treatment
KW - Multiple sclerosis
KW - Pharmacovigilance
KW - Telemedicine
UR - http://www.scopus.com/inward/record.url?scp=85107740699&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2021.577627
DO - 10.1016/j.jneuroim.2021.577627
M3 - Review Article
C2 - 34139567
AN - SCOPUS:85107740699
VL - 357
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
SN - 0165-5728
M1 - 577627
ER -